Merck & Co.’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly diagnosed patients with advanced non-small cell lung cancer in a highly anticipated study.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it was not proving effective.
Roche temporarily halted recruiting patients to the company’ s Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths.
vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in the Phase III STEADFAST clinical trial. The new drug candidate was being evaluated in patients with mild Alzheimer’s disease.
Alzheimer’s researchers proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline.
Menlo Therapeutics’ stock dropped 55 percent in premarket trading after the company’s serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.
AbbVie announced positive top-line data from the company’s Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate-to-severe rheumatoid arthritis.
Israel’s Therapix Biosciences announced positive results from a Phase IIa trial of its cannabinoid-based drug to treat Tourette syndrome (TS), sending the company’s stock price jumping.
Merck & Co.’s blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial.
An independent committee concluded that Inctye Corp.’s drug for a type of skin cancer in combination with Merck & Co.’s Keytruda failed to meet the main goal in a late-stage study.
An experimental smartphone application could monitor changes in Parkinson’s disease symptoms throughout the day, sending data to doctors to help them treat patients, U.S. researchers say.
Eli Lilly and Co.’s cancer drug Cyramza helped patients with liver cancer live longer, meeting the main goal of a late-stage trial four years after failing a prior study.
An experimental smartphone app might be an effective alternative to a traditional method of assessing circulation in people who need surgery to restore normal blood flow to the heart, a small study suggests.
As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.
A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.
Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.
La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.
An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.